Skip to main content
Premium Trial:

Request an Annual Quote

Burnham Institute Licenses HuCAL GOLD Antibodies From Morphosys

NEW YORK (GenomeWeb News) — The Burnham Institute will use Morphosys’ HuCAL GOLD-based antibodies for medical research, Morphosys said today.
HuCAL GOLD was developed by AbD Serotec, a MorphoSys subsidiary, and will be used to “identify and validate target molecules with potential medical implications” to help the Burnham Institute advance a number of ongoing programs.
MorphoSys said it will retain the commercial rights to all antibodies derived from the collaboration, and will distribute them through Serotec.  
Simon Moroney, MorphoSys’ CEO, called the potential access to disease-related target molecules a “key asset,” and said the contract could help both the company’s Serotec division and its long-term therapeutic business.

The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.